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OBJECTIVES: Hereditary angioedema (HAE) is a rare and potentially serious dis-
ease. Due to its rarity, there are very few epidemiological and therapeutic data on
this disease. The objectives of this study were to generate new information describ-
ing HAE patients and their symptoms, costs of therapeutic management, and im-
pact on health-related quality of life (HRQoL). METHODS: A one-year retrospective
observational study was conducted involving 306 HAE patients across 19 French
medical centres. Data were collected on disease pathology, management,, re-
sources and health-related quality of life based on the SF-36. RESULTS: 64.1% of
patients had type I and/or II HAE, whilst 35.9% of patients had type III. The initial
symptoms appeared in adolescents for type I/II HAE and in young adults for type III
HAE. Across all HAE types, 87.4% of patients had already experienced at least one
severe (life threatening) event related to the pathology and had an average of 8.5
episodes in the prior year. Out of 883 episodes, hospitalisation was necessary in
11.4% of episodes. An ICU stay was needed in 13.8% of the hospitalised episodes,
and 3 of these stays necessitated intubation. 55.2% of the patients had ongoing
long-term prophylactic treatment. The annual per-patient cost of HAE episodes
(treatment, hospitalisation) was €4892 for type I/II and €3313 for type III. As com-
pared with a population of patients with allergies, patients suffering from HAE
have a decrease in their SF-36 scores in the areas of mental health and social
well-being, as well as in most domains of physical health. Notably, there is a sig-
nificant degradation in the SF-36 scores of patients when the number of episodes
increases. CONCLUSIONS: HAE is a disease which reduces the QoL and has a high
cost of treatment
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OBJECTIVES: To establish the relationship between cardiovascular risk (CVR) and
health-related quality of life (HRQoL), as well as the presence or absence of comor-
bidities, in a Spanish hypertensive population. METHODS: Epidemiological, cross-
sectional, multicenter study conducted in adult patients with essential hyperten-
sion of1 year of evolution. Patients were stratified in 5 categories according to the
CVR within 10 years (ESH/ESC, 2007): average, low added, moderate added, high
added and very high added CVR. HRQoL was measured by MINICHAL question-
naire. It comprises 2 domains (mental status and somatic manifestations) referred
to the past week. Overall scores range from 0 to 48, with higher scores representing
worse HRQoL. Presence of kidney and cardiovascular disease was evaluated.
RESULTS:A total of 6,654 patients (55.2% male) were assessed; median age (Q1, Q3)
63.0 (55.0, 72.0) years and time since hypertension diagnosis 6.5 (2.9, 10.7) years.
Average CVR was presented in 3.5%, low added in 13.6%, moderate added in 12.8%,
high added in 39.0% and very high added in 31.0% of patients. Overall MINICHAL
scores ranged from 4.0 (2.0, 8.0) in patients with average CVR to 11.0 (5.0, 18.0) in
patients with very high added CVR (p0.0001). Mental status and somatic mani-
festations domains scores ranged from 4.0 (1.0, 6.0) for average CVR to 8.0 (4.0, 13.0)
for very high added CVR, and from 0.0 (0.0, 2.0) for average CVR to 3.0 (1.0, 6.0) for
very high added CVR, respectively (p0.0001, in both cases). Overall MINICHAL
scores related to comorbidities (presence vs. absence) were: kidney disease 13.0
(7.0, 20.0) vs. 7.0 (3.0, 12.0) and cardiovascular disease 10.0 (5.0, 17.0) vs. 6.0 (3.0,
12.0), [p0.0001, in both cases]. CONCLUSIONS: Hypertensive patients with in-
creased CVR show significant worse HRQoL, in both mental status and somatic
manifestations domains. The presence of comorbidities is associated with a worse
HRQoL.
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OBJECTIVES: To analyze, for the first time in a large Spanish population of heart
failure pts, quality of life according to NYHA class II, III or IV using generic and
specific quality of life questionnaires. METHODS: A descriptive analysis of a mul-
ticenter, prospective observational study was performed. Pts who met inclusion
criteria were followed-up for a period of 12 months, with 3 visits programmed at
baseline, 6 months and 12 months. A total of 9 Spanish hospitals were involved in
the study. Questionnaires used to measure quality of life were: EQ-5D (generic
questionnaire), Minessotta living with heart failure- MLWHF (specific question-
naire) and Barthel Index (index of independence). RESULTS: A total of 330 pts
completed the study, 74.2% men, mean age was 62.9 years. 82.4% were in NYHA
class II, 16.4% NYHA class III and 1.2% NYHA class IV. A total of 20 pts died along the
period of study and 25 pts did not complete follow up. Significant differences were
observed in Barthel Index’s scores depending on class: class II 97.2  7.3 vs. Class
III-IV 91.4  14.3. Related to EQ-5D scores, individuals in class II had a mean value
of 0.8058  0.2048 (out of 1), and mean VAS value of 56.75  17.39 (out of 100).
Individuals in NYHA class III-IV had a mean value of 0.6135  0.3032 (out of 1) and
mean VAS value of 50.45  20.24 (out of 100). In a MLWHF questionnaire analyses,
pts in NYHA class II showed a mean score of 29.81 18.57 while pts in NYHA class
III-IV showed a mean score of 48.53  17.97. CONCLUSIONS: Chronic heart failure
patients in NYHA III and IV seemed to have a higher grade for physical disability
and worse health-related quality of life compared to patients in NYHA II and pop-
ulation of similar age.
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OBJECTIVES: ACS encompasses a spectrum of clinical presentations arising from
the progression of coronary artery disease including: unstable angina, non-ST seg-
ment elevation myocardial infarction (NSTEMI) and ST segment elevation myocar-
dial infarction (STEMI). The epidemiology of ACS varies internationally with shift-
ing incidence related to changes in lifestyle over time with broad implications for
health care systems. This review focuses on the economic and humanistic burden
of ACS. METHODS: A systematic electronic literature search was conducted to
identify published reports from 1965 through 2009 for ACS. Abstracts from the
initial search were reviewed to identify relevant papers. A full review was con-
ducted on articles that met general inclusion criteria. Reference lists were hand
searched to identify additional data. Studies not available in English were excluded.
RESULTS: ACS has been associated with large reductions in health-related quality
of life (HRQOL). Statistically significant declines in both the physical and social
functioning domains of the SF-36 have been reported for individuals with MI, in
particular, even years after the clinical event. However, such research is limited to
specific populations and particular clinical events with variable findings across
studies. Economic models have used utility values for ACS ranging from 0.61-0.93
(scale:0-1), depending upon age group and the clinical presentation of interest. A
study of five European countries shows that economic costs also vary. Annual cost
per patient ranged from €7,009 (UK) to €12,086 (Italy), with hospitalizations ac-
counting for 50% of the total, on average, and pharmaceutical expenditures com-
prising between 14% (Spain) to 23% (Germany) of ACS total cost. CONCLUSIONS:
ACS is a major source of morbidity and is associated with significant economic
burden on health care systems, though the estimated impact on HRQOL varies by
country, clinical presentation and metric. Future therapies for ACS may offer op-
portunities to reduce some of the economic and humanistic burden of ACS.
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OBJECTIVES: Data seldom report the experience of chronic stable angina (CSA)
directly perceived by patients. This qualitative work aimed to explore how patients
perceive CSA and its impact on their life in order to optimise communication
between the doctor and their patient in the decision-making process. METHODS:
CSA patients with and without professional activity and treated with the most
frequent anti-anginal therapeutic strategies were recruited. They were inter-
viewed face-to face, based on a guide specifically designed for the purpose of the
study including questions on knowledge and beliefs, as well as on impact and
management of CSA. Recruitment was completed when no additional information
was obtained with the last interview, thus reaching saturation of the themes in-
vestigated and allowing building the comprehensive picture of patients’
perception. RESULTS: Symptoms perceived by CSA patients are cardiac pain, fa-
tigue, breathlessness and increased heart rate. The disease impairs patients’ daily
life such as physical activities (in particular walking/running, climbing stairs/hill,
and holding/carrying heavy things), work, family, sexual and social life and leisure
activities, in addition to psychological/emotional status. In order to avoid symp-
toms, treated patients adopt coping strategies such as anticipating, avoiding or
segmenting efforts, limiting/taking things easy, getting help, initiating healthy life-
style. For those who live with partners they mainly delegate treatment manage-
ment to them. Saturation was reached with the sample size population (n25).
CONCLUSIONS: CSA has detrimental impact on patients’ lives. Treated patients
adopt various coping strategies to help them live with their disease and lessen their
symptoms. This exploratory work will help to better understand the disease and
assess benefits of anti-anginal treatment from a patient’s perspective. This is likely
to facilitate patient-doctor communication in the decision-making process.
PCV123
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OBJECTIVES: The objective of this study was to compare attenders’ and non-at-
tenders’ preferences in relation to participation in lifestyle disease screening.
METHODS: During a screening trial of about 25,000 male citizens between the age
of 65 and 75, 2,119 invitees were sampled. The screening programme comprised a
test for abdominal aortic aneurysm, hypertension and peripheral artery disease,
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with relevant follow up for positive tests. Prior to the test, attenders were given a
questionnaire about their doubt and arguments in relation to the participation
decision, including different willingness-to-pay (WTP) questions. Non-attenders
were mailed a similar questionnaire. RESULTS: 70% responded to the question-
naire, which lead to a study sample of 1,053 attenders and 435 non-attenders.
Among attenders, 5% had doubt about participation and the most frequent argu-
ment was that they did not want to know about the test result. Among non-attend-
ers, 46% would reconsider attendance after further information, the main argu-
ment for doubt being the same as for attenders. Further arguments were self-
perceived low risk and the trouble and costs associated with attending. Attenders
valued the programme significantly higher than non-attenders but this was sensi-
tive to exclusion of bidders who did not pass a simple test for internal consistency
of the reported WTP. Doubt about participation was associated with significantly
lower WTP among attenders whereas the opposite was the case for non-attenders.
Amongst those in doubt, the WTP was the same for attenders and non-attenders.
CONCLUSIONS:Up to half of the non-attenders appeared to have doubt about their
decision, which presents a potential for increasing the participation rate. Non-
attenders in doubt about their participation decision value the programme at a
similar level as attenders in doubt, suggesting that non-attenders in doubt do not
differ significantly in their base-line valuations from those of the individuals in
doubt who choose to attend.
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OBJECTIVES: Generic reference pricing of medicines was introduced in Finland in
April 2009. The system restricts the amount of reimbursement paid to a consumer,
thus creating a financial incentive for the consumer to accept the switch to a
reference priced product. The aim of this study was to assess the impact of refer-
ence pricing on consumer’s choice, and to analyze the factors associated with the
choice of an originator drug priced higher than the reference price.METHODS: The
data used in this study was collected from the Social Insurance Institute=s prescrip-
tion register. Data covers the records of the purchases in five active ingredient
groups (atorvastatin, simvastatin, risperidone, olanzapine, quetiapine) by a sample
population from January 2008 to August 2010. Data includes information of the
consumer’s socio-demographic characteristics and income, and of the prescribed
and purchased product. Logistic regression analysis and logistic multilevel regres-
sion analysis were used to examine the factors associated with a consumer’s orig-
inator drug choice. RESULTS: After the introduction of reference pricing the use of
originator drugs declined but some of the consumers chose originator drugs even
when priced higher than reference price. An important factor explaining the prob-
ability of choosing over reference priced originator drugs is habit, the choice history
of the patient. In some active ingredient groups’ higher age, higher income and
female sex increased the probability of originator drug choice. The right to special
reimbursement mainly lowered the probability. CONCLUSIONS: In earlier studies
it has been shown that some of the consumers have prejudices on generic products
and they want to stick with doctor=s choice of medicine. The results of our study
also indicate that doctor=s primary decision of the prescribed medicine probably
has an influence on some consumers choices and that decision has an important
role in promoting the use of cheaper, generic products.
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OBJECTIVES: Atrial fibrillation (AF) is the most common cardiac arrhythmia in
clinical practice with increasing prevalence in the aging population. The objective
of our study was to evaluate the impact of AF on secondary care costs in Scotland.
METHODS: Patient hospitalisation data collected by the Information and Statistics
Division (ISD) of the Scottish National Health Service (NHS) from 2004 to 2008 were
analysed to estimate the trends in hospital episodes in the 5.2 million population of
Scotland. The associated costs were estimated using the tariff prices in Scotland for
the respective years. RESULTS: Over the 5 year period, the number of patients
hospitalised for AF increased by 21.0% to 26,510 patients in 2008 from 21,907 in
2004, with a total of 162,449 hospital admissions for AF over this period and ac-
counting for 20.8% of total cardiovascular (CV) hospitalisations in 2008. The total
inpatient bed days in 2008 were 394,128; a 14.5% increase during this time, with
mean length of inpatient stay for AF higher than the mean for all cardiovascular
conditions (10.9 vs 8.7). The total cost (inpatient and day cases) attributable to AF
increased from £138.9 million in 2004 to £162.5 million in 2008, accounting for a
quarter (23.8%) of all CV hospital costs in Scotland. Overall, the burden of AF was
higher among women and increased progressively with age. CONCLUSIONS: AF
presents a significant and increasing burden on hospital care in Scotland. As a
proportion of total CV burden, AF accounts for nearly a quarter and is increasing at
a relatively higher rate.
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OBJECTIVES: To evaluate current practice, characteristics of treated population,
utilization of resources and direct medical costs related to anticoagulation treat-
ment in 6 indications in Poland. METHODS: The study consisted of 3 parts: cross-
sectional study (performed in hospitals and open care), retrospective chart review
and experts opinion-based study. The study was carried out between December 20,
2010 and March 15, 2011. Patients data on anticoagulation therapy or with atrial
fibrillation or immobilized were included in cross-sectional part (2021 hospitalized
patients and 4175 monitored in outpatient treatment). Documentation of 1752 pa-
tients treated for stroke, myocardial infraction, coronary artery disease, deep vein
thrombosis, pulmonary embolism or atrial fibrillation or undergoing surgery (e.g.
hip or knee replacement) was included in retrospective chart review. A total of 546
face-to-face interviews with physicians of different specializations (orthopedists,
general and vascular surgeons, cardiologists, neurologists, general practitioners
and rehabilitation therapists) were conducted in opinion-based study. Projection of
treated population was made in order to generalize the results to the whole
country. RESULTS: About 150,000 prescriptions for anticoagulants were made
within 2 weeks of study. Approximately 36,000 patients daily were treated with
anticoagulants in hospitals. The main reason for administrating anticoagulants in
outpatient treatment was primary stroke prevention in patients with atrial fibril-
lation (28%), secondary prevention of venous thromboembolism (18%) and second-
ary stroke prevention in atrial fibrillation (14%). During hospitalization anticoagu-
lants were administered mainly as a prevention of venous thromboembolism in
patients who underwent a surgery (33%), or were immobilized due to other reasons
(17%). Vitamin K antagonists accounted for 65% of market in outpatient practice,
while low-molecular-weight heparins (LMWH) constituted 77% in inpatient
treatment. CONCLUSIONS: Administration of anticoagulants in inpatient treat-
ment is usually surgery-related, while in outpatient treatment the most common
reason is stroke prevention. Oral anticoagulants are usually administrated in out-
patient treatment, while LMWHs are most commonly used in hospitals.
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OBJECTIVES: To assess the time to initiation of therapy with an oral antihypergly-
caemic agent (OAHA) or statin in patients with newly diagnosed type 2 diabetes
mellitus (T2DM). METHODS: In a retrospective US cohort study using the General
Electric electronic medical record database, patients 18 years were included if
they were newly diagnosed with T2DM between January 1, 2004 and December 31,
2005 (index period), with last pre-index A1C 7%, and had not received any anti-
hyperglycaemic agents within the 2 years prior to diagnosis (index date). In addi-
tion, patients were required to be eligible for statin therapy per 2008 American
Diabetes Association recommendations but not on a statin within 1 year prior to
index date. Patients had to have medical records 1 year prior to (baseline) and at
least 2 years after (follow up) the index date. Initiation of OAHA and statin was
determined based on the first prescription record for each therapeutic class.
RESULTS: Of the 2254 patients with newly diagnosed T2DM (58% male), mean age
at index date was 58 years. The most recent mean HbA1c before diagnosis was 8.5%
and mean LDL-cholesterol was 106 mg/dL. Further, 21% of patients had pre-exist-
ing overt CV disease, 40% had dyslipidaemia, 37% were obese, and 11% were smok-
ers. After 2 years of follow up, 48% and 53% of patients initiated an OAHA and
statin, respectively, with 18% initiating both agents on the same day. The median
time from diabetes diagnosis to initiation of OAHA was 119 days and 325 days for
statin initiation. Median time from initiation of OAHA to initiation of statin was 69
days. CONCLUSIONS: Treatment with OAHA and/or statin was suboptimal after
years years in patients with newly diagnosed T2DM who were also eligible for
statin therapy. Of those treated, patients initiated treatment earlier with OAHA
than with statin.
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OUTCOMES AND RESOURCE USE ASSOCIATED WITH PATIENTS BEING
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OBJECTIVES: To describe the resource use and level of anticoagulation control
associated with different patient characteristics within a secondary care anticoag-
ulation service. METHODS: An observational research study was conducted in one
secondary-care anticoagulation service between March and June 2010. Retrospec-
tive data were collected on patient characteristics (age, diagnosis, co-morbidities,
concomitant medications), number of INR (International Normalised Ratio, pro-
thrombin time) visits and time in target range (TTR) from all patients registered
with the service after January 1, 2008 and 3 months before data collection. Data
were analysed by initiation (0-12 weeks after initiation of warfarin) and mainte-
nance ( week 12) phases and correlations run to explore relationships. RESULTS:
Data were collected from 288 patients; mean age 67 years, 54% male. 45% had atrial
fibrillation (AF), 37% were receiving warfarin for venous thromboembolism treat-
ment or prevention (VTE), 18% other reasons (e.g cardiac valves). Mean number of
INR visits was 8.4 during initiation and 1.6 per month during maintenance for
patients with AF and 10.2 and 1.9 respectively for VTE. Mean TTR was 45% during
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